Drug intelligence / Profile preview

CAR-NK IND Pipeline 6

Development stage: Preclinical
Lead developer: BioCreatrix
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CAR-NK IND Pipeline 6 is an investigational chimeric antigen receptor (CAR) engineered natural killer (NK) cell therapy being developed by BioCreatrix in collaboration with CBiolab. The therapy involves engineering NK cells to express a tri-specific CAR that targets three unspecified tumor-anchoring antigens. This multi-antigen targeting strategy is intended to increase the precision of tumor cell recognition and reduce the likelihood of immune evasion through antigen loss. The program is currently in the IND-enabling phase for the treatment of various cancers, leveraging the innate cytotoxicity of NK cells enhanced by targeted CAR engineering.

Other names: BioCreatrix CAR-NK cell therapy

Beyond the preview

Go deeper on CAR-NK IND Pipeline 6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-NK IND Pipeline 6.

Explore the full profile